Tag: Cardioversion

Cardioversion without adequate anticoagulation carries a thromboembolic risk of up to 5-7% in the first 30 days. For this reason, knowing *when to start anticoagulation after cardioversion* is a critical decision in managing patients with atrial fibrillation to mitigate stroke risk.

Flecainide is nearly completely absorbed by the body, with a high bioavailability of 85-90%. Understanding how long does it take for flecainide to be effective is crucial for patients and providers, as the timeline depends heavily on whether it's used for acute cardioversion or chronic rhythm control.